Hinova Pharmaceuticals Inc. A (688302) - Net Assets
Based on the latest financial reports, Hinova Pharmaceuticals Inc. A (688302) has net assets worth CN¥1.14 Billion CNY (≈ $166.44 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.39 Billion ≈ $203.78 Million USD) and total liabilities (CN¥255.12 Million ≈ $37.33 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Hinova Pharmaceuticals Inc. A to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.14 Billion |
| % of Total Assets | 81.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | 20.9% |
| 10-Year Change | N/A |
| Growth Volatility | 50.53 |
Hinova Pharmaceuticals Inc. A - Net Assets Trend (2019–2024)
This chart illustrates how Hinova Pharmaceuticals Inc. A's net assets have evolved over time, based on quarterly financial data. See Hinova Pharmaceuticals Inc. A defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hinova Pharmaceuticals Inc. A (2019–2024)
The table below shows the annual net assets of Hinova Pharmaceuticals Inc. A from 2019 to 2024. For live valuation and market cap data, see Hinova Pharmaceuticals Inc. A (688302) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.19 Billion ≈ $174.46 Million |
-12.79% |
| 2023-12-31 | CN¥1.37 Billion ≈ $200.05 Million |
-13.77% |
| 2022-12-31 | CN¥1.59 Billion ≈ $231.99 Million |
+101.00% |
| 2021-12-31 | CN¥788.76 Million ≈ $115.42 Million |
-20.02% |
| 2020-12-31 | CN¥986.15 Million ≈ $144.30 Million |
+2855.76% |
| 2019-12-31 | CN¥-35.78 Million ≈ $-5.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hinova Pharmaceuticals Inc. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 132526989861.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥2.68 Billion | 224.95% |
| Total Equity | CN¥1.19 Billion | 100.00% |
Hinova Pharmaceuticals Inc. A Competitors by Market Cap
The table below lists competitors of Hinova Pharmaceuticals Inc. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SA Corporate Real Estate Fund Managers Ltd
JSE:SAC
|
$515.26 Million |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
|
$515.33 Million |
|
Hainan Pearl River Holdings Co Ltd
SHE:000505
|
$515.34 Million |
|
Guangdong Sanhe Pile Co Ltd
SHE:003037
|
$515.46 Million |
|
Taekwang Ind
KO:003240
|
$515.04 Million |
|
Guangdong Dcenti Auto-Parts Stock Ltd Co
SHG:603335
|
$514.99 Million |
|
MH Robot & Automation Co. Ltd.
SHE:301199
|
$514.92 Million |
|
Tianjin Tianbao Infrastructure Co Ltd
SHE:000965
|
$514.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hinova Pharmaceuticals Inc. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,367,090,349 to 1,192,245,115, a change of -174,845,234 (-12.8%).
- Net loss of 199,495,736 reduced equity.
- Other factors increased equity by 24,650,502.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-199.50 Million | -16.73% |
| Other Changes | CN¥24.65 Million | +2.07% |
| Total Change | CN¥- | -12.79% |
Book Value vs Market Value Analysis
This analysis compares Hinova Pharmaceuticals Inc. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.95x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥-0.49 | CN¥35.55 | x |
| 2020-12-31 | CN¥13.28 | CN¥35.55 | x |
| 2021-12-31 | CN¥7.97 | CN¥35.55 | x |
| 2022-12-31 | CN¥16.01 | CN¥35.55 | x |
| 2023-12-31 | CN¥13.81 | CN¥35.55 | x |
| 2024-12-31 | CN¥12.04 | CN¥35.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hinova Pharmaceuticals Inc. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54382.77%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-16.73%) is above the historical average (-24.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -2642.93% | 0.09x | 0.00x | CN¥-108.09 Million |
| 2020 | -49.67% | 0.00% | 0.00x | 1.21x | CN¥-588.46 Million |
| 2021 | -38.82% | 0.00% | 0.00x | 1.25x | CN¥-385.06 Million |
| 2022 | -19.02% | -18264.52% | 0.00x | 1.09x | CN¥-460.05 Million |
| 2023 | -21.52% | 0.00% | 0.00x | 1.09x | CN¥-430.87 Million |
| 2024 | -16.73% | -54382.77% | 0.00x | 1.14x | CN¥-318.72 Million |
Industry Comparison
This section compares Hinova Pharmaceuticals Inc. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hinova Pharmaceuticals Inc. A (688302) | CN¥1.14 Billion | 0.00% | 0.22x | $515.09 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501… Read more